Nervous Disorder TRIZ Cases

Selective estrogen receptor modulators enhance oligodendrocyte precursor differentiation to restore myelin integrity despite inflammatory barriers.

A pliable mucoadhesive oral composition adheres to the treatment site and slowly dissolves to deliver active ingredients.

Dimeric peptide analogues linked by PEG chains target PDZ1-2 domains of PSD-95 to enhance binding affinity and blood-brain barrier permeability.

Collaborative genome-wide association studies identify novel genetic markers to diagnose Alzheimer's disease beyond the APOE locus.

Prevotella histicola strain C reduces neuroinflammation side effects by increasing regulatory T cells and IL-10.

Myelin nanovesicles transport therapeutic agents across the blood-brain barrier using native lipid-protein structures.

Engineered ActRIIB5 receptor binds and inhibits myostatin, activin A, and GDF-11 to increase lean muscle mass.

Chemically modified antisense oligonucleotides degrade C9ORF72 RNA to lower nuclear foci counts, addressing ineffective ALS and FTD therapies.

Alpha7 nicotinic acetylcholine receptor positive allosteric modulators alleviate behavioral impairments by reducing astrocyte activation and p38 MAPK signaling.

Cyclic polypeptides derived from acetylcholinesterase block calcium influx via alpha7 receptor modulation.

AQ2S crosses the blood-brain barrier to inhibit caspase activity and prevent neuronal death after acute injury.

Extracting a 5-to-15 amino acid core reduces synthesis complexity while maintaining high fungicidal activity against systemic infections.

Multi-layered torsemide tablet segments doses to maintain steady plasma levels, resolving rapid fluctuation bottlenecks in heart failure therapy.

Ang-(1-7) derivative oligopeptides cross the blood-brain barrier to treat cognitive dysfunction caused by congestive heart failure.

A particulate oral pharmaceutical composition disperses hydrophobic liquid containing active ingredients within a water-soluble polymer matrix.

Substituted monocyclic heteroaryl compounds of Formula I reduce Huntingtin protein levels in cells.

Human acidic fibroblast growth factor injection promotes neural regeneration through biological action on nerve fibers.

Administering pertussis toxin mitigates clinical motor symptoms and inhibits microglia migration in autoimmune disease models.

Optimized Formula I mTOR inhibitors cross the blood-brain barrier to treat Huntington's disease and epilepsy without cytotoxicity.

Gamma-diketone compounds activate the Wnt/beta-catenin signaling pathway to stimulate stem cell proliferation and osteoblast differentiation.

TLR3 antibody antagonists bind specifically to toll-like receptor 3 to inhibit biological activity and block downstream signaling pathways.

Fusing erythropoietin to a hybrid IgG-IgD Fc domain resolves the trade-off between in vivo stability and undesired immune responses, extending serum half-life.

Polyphenolic compositions inhibit bacterial and human amyloid formation in the gastrointestinal tract, bypassing blood-brain barrier constraints.

Pure 7-OH-CBD and 7-OH-CBDV metabolites enhance seizure control in treatment-resistant epilepsy via parameter changes.

Gelling agents promote rapid shell solidification during vibrating nozzle production, resolving emulsion instability and preventing active ingredient loss.

Alpha-1-antitrypsin inhibits TACE activity to enhance myelin production, addressing ineffective treatments for neuroinflammatory diseases.

Replacing hydrophobic residues with hydrophilic ones in transmembrane helices yields stable, soluble GPCRs for structural studies.

Magnetic activated cell sorting isolates pluripotent stem cells from umbilical cord tissue using specific surface markers.

Segmented IGF1 peptide crosses the blood-brain barrier to restore synaptic function without invasive delivery methods.

Targeting the GLP-1 receptor over the glucagon receptor improves glucose tolerance while maintaining potency for treating obesity.

Engineered monoclonal antibodies target soluble A beta oligomers without binding monomers, resolving specificity issues in Alzheimer's diagnostics.

Clusterin polypeptides bind and inhibit MMP enzymes, reducing tissue degradation in dry eye disease.

Lormetazepam combined with macrogol solubilizer produces an opiate-analogous Straub phenomenon.

Combining short-acting and long-acting hypnotic agents creates a synergistic pharmaceutical composition that improves sleep induction and maintenance.

Antisecretory factor regulates ion transporters to normalize intracellular pressure, improving anticancer drug delivery while reducing toxicity.

Heteroaryl substituted nicotinamide compounds inhibit IRAK-4 to treat inflammatory diseases.

Follistatin-Fc fusion extends serum half-life to treat Duchenne muscular dystrophy by reducing muscle wasting and fibrosis.

Genetically encoded blue-light opsins replace mechanical electrodes, enabling selective neuron stimulation without lead migration.

Correcting the amino acid substitution at position 176 from proline to arginine resolves clinical response variability in dopaminergic neuron protection.

Optimized antibody sequences achieve sub-50 picomolar dissociation constants, enhancing therapeutic efficacy while minimizing adverse reactions.

Cyclization and poly-arginine conjugation stabilize linear peptides, enabling effective intracellular delivery for neuroprotection.

Biphenyl derivatives antagonize NMDA receptors to reduce neurological impairment while avoiding loss of consciousness.

Targets HERV-W envelope protein and nitric oxide pathways to reverse remyelination blockade in progressive multiple sclerosis patients.

Isolated mitochondria lower beta-amyloid peptide concentration by decreasing beta-secretase and gamma-secretase activity to improve memory deficits.

Multifunctional polypeptides use a PEST motif to target specific proteins for proteasome degradation.

(-) stereoisomers of N-substituted arylcyclopropylamine compounds selectively inhibit LSD1 while minimizing MAO-A inhibition to improve therapeutic safety.

Incorporating non-naturally encoded amino acids at positions 36 and 111 reduces immunogenicity while maintaining therapeutic efficacy.

Biocompatible polymeric mini-tubes diffuse compression forces to alleviate intrinsic intra-parenchymal pressure and promote nerve regeneration.